PRLog (Press Release) - Aug 12, 2012 - MONMOUTH JUNCTION, NJ.– UPCK™ Urine Protein Enrichment/Concentration Kit features a urinary protein enrichment optimized protocol for sample preparation and downstream analysis of urine samples using CE-MS, LC-MS, LC-MS/MS, 1-D gel analysis in combination with nano-LC MS/MS plus LTQ-FT ultra, 2-DE-MS and Multidimensional Protein Identification Technology (MudPIT) proteomic biotechniques. It is compatible with 96 well high throughput format and mild elution maintains tertiary structure and simple transfer to secondary analysis. UPCK™ Urine Protein Enrichment/Concentration Kit is ideal for mining urinary biomarkers for diabetes, diabetic nephropathy, and nondiabetic proteinuric renal diseases. Utilizing high-resolution capillary electrophoresis coupled with electrospray-ionization mass spectrometry biomarkers could be validated in blinded data sets in order to distinguish diabetic patients from healthy individuals. Researchers could identify differences in urinary biomarkers between diabetic patients having normoalbuminuria and signs of developing nephropathy. Such trends are used to identify patterns in a panel of biomarkers e.g. progression of diabetic nephropathy in patients with microalbuminuria and diabetes for early detection of disease. Urine stored in the bladder does not result in proteolytic degradation by endogenous proteases and it is ideal for protein analysis. Large volumes of urine can be processed rapidly within one hour from milliliters to liters.
Potential applications of UPCK™ Urine Protein Enrichment/Concentration Kit
Researchers Zurbig et al have published research in the journal Diabetes regarding urinary proteome analysis to predict diabetic nephropathy. Peptides and proteins in urine present from glomerular filtration, tubular secretion, epithelial cells in the kidney and urinary tract are a potential source of biomarkers for diabetic nephropathy and chronic renal disease.
Authors Theodorescu et al identified a urothelial carcinoma proteomic pattern model for predicting the presence of cancer and linked it to fibrinopeptide A-a, a biomarker of ovarian cancer and gastric cancer. Researchers also sequenced diagnostic polypeptides for urothelial carcinoma.
UPCK™ Urine Protein Concentration Kit has been especially optimized for proteomic studies of urine proteins.
For more information click here:
http://www.biotechsupportgroup.com/node/245
About Biotech Support Group LLC
Biotech Support Group LLC is a leading provider of genomics and proteomics sample preparation products and enrichment reagent kits as well as integrated biotechnology services for life sciences research, biomarker and drug discovery. Based in New Jersey, it’s principal products include: AlbuVoid™ for albumin depletion, Cleanascite™ for lipid adsorption and clarification, NuGel™ for passivated silica-based affinity chromatography, and ProCipitate™ & ProPrep™ for nucleic acid isolation. Currently, Biotech Support Group LLC and ProFACT Proteomics Inc., are collaborating on the development of a proteomics platform used in functional profiling for proteomic analysis and a separations method for generating sub-proteomes used in biomarker and functional proteomic prospecting. For more information, go to: www.biotechsupportgroup.com.
CONTACT:
Dr.Swapan Roy
Biotech Support Group
1 Deer Park Drive, Suite M,
Monmouth Junction, NJ 08852, USA
732-274-2866
sales@biotechsupportgroup.com
References
1.Kistler AD, Mischak H, Poster D, Dakna M, Wuthrich RP, Serra AL: Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int 2009, 76:89-96.
2.Drube J, Schiffer E, Mischak H, Kemper MJ, Neuhaus T, Pape L, et al.: Urinary proteome pattern in children with renal Fanconi syndrome. Nephrol Dial Transplant 2009, 24:2161-2169.
3. Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, et al.: Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008, 19:1283-1290
4.Fliser D, Novak J, Thongboonkerd V, Argiles A, Jankowski V, Girolami M, et al.: Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 2007, 18:1057-1071.
5.Julian BA, Wittke S, Novak J, Good DM, Coon JJ, Kellmann M, et al.: Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis 2007, 28:4469-4483.
6.Dihazi H, Muller GA, Lindner S, Meyer M, Asif AR, Oellerich M, et al.: Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin Chem 2007, 53:1636-1645.
7.Mischak H, Kaiser T, Walden M, Hillmann M, Wittke S, Herrmann A, et al.: Proteomic analysis for the assessment of diabetic renal damage in humans. Clin Sci (Lond) 2004, 107:485-495.
8.Meier M, Kaiser T, Herrmann A, Knueppel S, Hillmann M, Koester P, et al.: Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. J Diabetes Complications 2005, 19:223-232.
9.Rossing K, Mischak H, Parving HH, Christensen PK, Walden M, Hillmann M, et al.: Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int 2005, 68:193-205.
10.Nguyen MT, Ross GF, Dent CL, Devarajan P: Early prediction of acute renal injury using urinary proteomics. Am J Nephrol 2005, 25:318-326.
11.Zurbig P, Jerums G, Hovind P, Macisaac R, Mischak H, Nielsen SE, Panagiotopoulos S, Persson F, Rossing P. Diabetes. 2012. Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy
12.Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF.Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncology. 2006 Mar;7(3):230-40
Photo:
http://www.prlog.org/11947848/1
